The safety and possible side effects of orforglipron were found to be similar to those of other GLP-1 receptor agonists
GLP-1 Weight-Loss Drugs Found to Work in Rare Genetic Obesity Key Takeaways: GLP-1based medicines reduced body weight and improved metabolic health in animals lacking the MC4R receptor, a critical regulator of appetite and body weight The findings suggest these therapies may work through alternative brain and peripheral pathways, offering potential treatment options for people living with rare genetic obesity Researchers highlight potential risks linked to lean mass loss, emphasising the importance of long-term monitoring and muscle-preserving treatment strategies Understanding genetic obesity and loss of appetite control For individuals born with certain genetic mutations affecting appetite regulation, managing body weight can resemble attempting to stop a vehicle with failing brakes
Last month, F&B giant Nestl launched Vital Pursuit, a new line of food products designed to accompany GLP-1 weight loss medication user s and those focused on weight management
Hims currently offers compounded semaglutide, the active ingredient in Novos Wegovy, at doses similar to those made by Novo
It also includes data only from people with diabetes, not the general population
FDA Label .
